Overall, our findings suggest that PPI treatment leads to a significant reduction in GRP78 expression in sorafenib-resistant HCC cells, consequently enhancing the anti-tumor activity of sorafenib against hepatoma growth, both in vitro and in vivo. This evidence concerns the gene HSPA5 and hepatocellular carcinoma.